---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002537"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:29:30.005952+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mallinckrodt to discontinue StrataGraft due to slow uptake; expects ~$15M in exit costs and impairment charge.

## Summary
- On Jan 4, 2024, committed to cease commercialization and wind down StrataGraft by end of Q1 2025.
- Pre-tax charges ~$15M excluding impairments: $5M termination benefits, $5M contract/lease termination, $5M other costs; mostly cash charges in Q1 2024.
- Impairment charge on StrataGraft inventory expected in Q1 2024 but amount not yet estimable due to fresh-start accounting from Nov 2023 bankruptcy emergence.
- Decision driven by slower-than-anticipated commercial uptake and clinical trial enrollment; evaluating sale or out-license.
- Majority of charges in Q1 2024, remainder through FY2024 and Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-002537
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 2.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/0001104659-24-002537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/tm242500d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002537
- JSON: https://secwatch.observer/filing/0001104659-24-002537.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002537.txt

## Key facts
- Restructurings & Charges
  Keenova Therapeutics plc announced a restructuring with charges of approximately $15 million affecting StrataGraft product (approximately $5 million of one-time termination benefits).
  - Type: restructuring
  - Charge: approximately $15 million
  - Affected area: StrataGraft product
  - Headcount: approximately $5 million of one-time termination benefits
  source text: the Company currently expects to incur pre-tax charges, exclusive of impairments, of approximately $15 million, which include (i) approximately $5 million of one-time termination benefits, (ii) approximately $5 million in contract and lease termination costs, and (iii) approximately $5 million of other associated costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/0001104659-24-002537-index.htm
- Restructurings & Charges
  Keenova Therapeutics plc announced a impairment affecting StrataGraft inventory.
  - Type: impairment
  - Affected area: StrataGraft inventory
  source text: the Company expects to recognize an impairment charge related to its existing StrataGraft inventory in the first fiscal quarter of 2024. The Company cannot currently estimate the size or materiality of the impairment charge because it is currently assessing the fair value of its assets as a result of the adoption of fresh-start accounting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000110465924002537/0001104659-24-002537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.